[go: up one dir, main page]

AR033379A1 - Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen - Google Patents

Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen

Info

Publication number
AR033379A1
AR033379A1 ARP010103052A ARP010103052A AR033379A1 AR 033379 A1 AR033379 A1 AR 033379A1 AR P010103052 A ARP010103052 A AR P010103052A AR P010103052 A ARP010103052 A AR P010103052A AR 033379 A1 AR033379 A1 AR 033379A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
group
alkyl
ring
attached
Prior art date
Application number
ARP010103052A
Other languages
English (en)
Inventor
Gilbert Lavielle
Olivier Muller
Mark Millan
Anne Dekeyne
Mauricette Brocco
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR033379A1 publication Critical patent/AR033379A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/201,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos de difenilurea de formula (1) en la cual R1, R2, R3 y R4 representan independientemente un átomo de hidrogeno, un átomo de halogeno o un grupo alquilo, alcoxi, hidroxi, alquiltio, mercapto, ciano, amino (opcionalmente substituido por uno o dos grupos alquilo), nitro, carboxi, alcoxicarbonilo, aminocarbonilo (opcionalmente substituido por uno o dos grupos alquilo) o carbamoilo, o en pares, forman conjuntamente con los átomos de carbono a los cuales están unidos, un anillo fenilo o un heterociclo aromático que tiene entre 5 y 7 miembros de anillo y que contiene entre 1 y 3 heteroátomos seleccionados entre nitrogeno, oxígeno y azufre, L1 y L2 cada uno representa un átomo de hidrogeno o conjuntamente forman un grupo -CH2-CH2-, X1 adosado en la posicion 2 o 3 del anillo aromático, representa un enlace, y en ese caso X2 representa un átomo de hidrogeno, un átomo de halogeno, un grupo alquilo, alcoxi, hidroxi, nitro o ciano, o un grupo amino (opcionalmente substituido por uno o dos grupos alquilo), o, X1 y X2, conjuntamente con dos átomos de carbono adyacentes a los cuales están unidos en la posicion 2, 3 o 4 del anillo aromático, forman un grupo cicloalquilo (C4-7), en el cual uno o dos grupos -CH2- del anillo cicloalquilo están opcionalmente reemplazados por un átomo de oxígeno o un grupo NH (opcionalmente substituido por un grupo alquilo), y en el cual un átomo de carbono del anillo cicloalquilo está substituido por el grupo G, X3 representa un átomo de hidrogeno, un átomo de halogeno, un grupo alquilo, alcoxi, hidroxi, nitro o ciano, o un grupo amino (opcionalmente substituido por uno o dos grupos alquilo), G representa un grupo seleccionado entre las formulas G1, G2, G3 y G4 en las cuales: las líneas entrecortadas indican la presencia opcional de un enlace doble, Alk representa un grupo alquileno (C1-6) lineal o ramificado en el cual, cuando G1 o G2 contiene un grupo imidazolina, el grupo Alk- está adosado en la posicion 2 del anillo, n es 0 o 1, T3 representa un grupo alquilo, arilo opcionalmente substituido, arilalquilo opcionalmente substituido, heteroarilo opcionalmente substituido o heteroarilalquilo opcionalmente substituido, T4 representa un grupo alquilo, arilo opcionalmente substituido, arilalquilo opcionalmente substituido, heteroarilo opcionalmente substituido o heteroarilalquilo opcionalmente substituido, enantiomeros y diastereoisomeros de los mismos, y también las sales de adicion de los mismos con un ácido o una base farmacéuticamente aceptable. Procedimiento para su preparacion y composiciones farmacéuticas que los contienen. Los compuestos son utiles como ligandos a2/5-HT2c mixtos y en consecuencia, son utiles en el tratamiento de la depresion, ansiedad, esquizofrenia, enfermedad de Parkinson, alteraciones cognitivas, alteraciones de la libido y disfuncion sexual, alteraciones del sueno, abuso de drogas, y alteraciones de comportamiento impulsivo.
ARP010103052A 2000-06-29 2001-06-27 Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen AR033379A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0008378A FR2810979B1 (fr) 2000-06-29 2000-06-29 Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
AR033379A1 true AR033379A1 (es) 2003-12-17

Family

ID=8851854

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103052A AR033379A1 (es) 2000-06-29 2001-06-27 Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen

Country Status (24)

Country Link
US (2) US6784183B2 (es)
EP (1) EP1170288B9 (es)
JP (1) JP3933889B2 (es)
KR (1) KR100485018B1 (es)
CN (1) CN1241916C (es)
AR (1) AR033379A1 (es)
AT (1) ATE273283T1 (es)
AU (1) AU780022B2 (es)
BR (1) BR0102607A (es)
CA (1) CA2352405C (es)
DE (1) DE60104776T2 (es)
DK (1) DK1170288T3 (es)
EA (1) EA005128B1 (es)
ES (1) ES2227088T3 (es)
FR (1) FR2810979B1 (es)
HK (1) HK1042698B (es)
HU (1) HUP0102723A3 (es)
NO (1) NO320310B1 (es)
NZ (1) NZ512658A (es)
PL (1) PL348392A1 (es)
PT (1) PT1170288E (es)
SI (1) SI1170288T1 (es)
TR (1) TR200402069T4 (es)
ZA (1) ZA200105394B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200306783A (en) * 2002-04-29 2003-12-01 Fmc Corp Pesticidal heterocycles
WO2004058722A1 (en) * 2002-12-24 2004-07-15 Arena Pharmaceuticals, Inc. Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
AU2004212985B2 (en) * 2003-02-20 2010-10-14 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
BRPI0412263B1 (pt) 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
FR2859723B1 (fr) * 2003-09-16 2005-10-21 Servier Lab Nouveaux derives de benzoindoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PT1663960E (pt) 2003-09-25 2011-12-16 Dompe Spa Amidinas e os seus derivados e composições farmacêuticas que os contêm
US7812176B2 (en) * 2004-03-23 2010-10-12 Arena Pharmaceuticals, Inc. Processes for preparing substituted N-aryl-N′-[3-(1H-pyrazol-5-YL) phenyl] ureas and intermediates thereof
PE20061130A1 (es) * 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
WO2006060762A2 (en) * 2004-12-03 2006-06-08 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
PL1858877T3 (pl) 2005-01-14 2014-08-29 Gilead Connecticut Inc 1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy
CN101160127A (zh) * 2005-01-19 2008-04-09 艾尼纳制药公司 用于预防或治疗进行性多灶性白质脑病而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
EP2018371B1 (en) 2006-05-18 2015-03-04 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
EP2527329A1 (en) 2006-05-18 2012-11-28 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
USRE45337E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
CN100390150C (zh) * 2006-06-05 2008-05-28 吴汝林 盐酸咪唑苯脲的制备方法
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
EP2142538B1 (en) * 2007-02-13 2011-10-26 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
WO2008100480A1 (en) 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−HT2Aセロトニン受容体に関連した障害の治療のための5−HT2Aセロトニン受容体のモジュレーターとしてのイミダゾ[1,2−a]ピリジン誘導体
US20110021538A1 (en) * 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US9034911B2 (en) * 2008-10-28 2015-05-19 Arena Pharmaceuticals, Inc. Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
TR201810399T4 (tr) * 2013-03-15 2018-08-27 Gilead Sciences Llc İndolamin 2,3-dioksijenaz (ıdo) inhibitörleri.
TWI704145B (zh) * 2015-06-05 2020-09-11 芬蘭商奧利安公司 新醫藥化合物
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
PL248268B1 (pl) * 2023-04-13 2025-11-17 Uniwersytet Medyczny W Lublinie 1-(1-fenyloimidazolin-2-ylo)-3-aryloalkilo pochodne mocznika oraz sposób ich wytwarzania i ich zastosowanie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR7909023A (pt) * 1979-08-23 1981-06-09 Caterpillar Tractor Co Dispositivos antitorcao para lagartas para veiculos do tipo de rastos e metodo
GB9313913D0 (en) * 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds
JPH09504004A (ja) * 1993-08-20 1997-04-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5ht1dレセプター拮抗薬用アミドおよび尿素誘導体
GB9420999D0 (en) * 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
WO1998024785A1 (en) * 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Indole-urea derivatives with 5-ht antagonist properties
WO1998047885A1 (en) * 1997-04-18 1998-10-29 Smithkline Beecham Plc A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity

Also Published As

Publication number Publication date
CN1241916C (zh) 2006-02-15
PT1170288E (pt) 2004-10-29
EP1170288B1 (fr) 2004-08-11
AU780022B2 (en) 2005-02-24
US7026357B2 (en) 2006-04-11
HK1042698B (zh) 2006-08-11
HU0102723D0 (en) 2001-08-28
FR2810979B1 (fr) 2002-08-23
EA200100600A2 (ru) 2002-02-28
JP2002037778A (ja) 2002-02-06
DE60104776D1 (de) 2004-09-16
NO320310B1 (no) 2005-11-21
SI1170288T1 (en) 2004-12-31
NZ512658A (en) 2002-10-25
EA200100600A3 (ru) 2002-04-25
EP1170288A2 (fr) 2002-01-09
AU5414401A (en) 2002-01-03
HK1042698A1 (en) 2002-08-23
EP1170288A3 (fr) 2002-01-16
NO20013254L (no) 2001-12-31
US6784183B2 (en) 2004-08-31
CA2352405A1 (fr) 2001-12-29
JP3933889B2 (ja) 2007-06-20
PL348392A1 (en) 2002-01-02
NO20013254D0 (no) 2001-06-28
US20020025965A1 (en) 2002-02-28
HUP0102723A2 (hu) 2002-03-28
ZA200105394B (en) 2002-01-31
KR20020002249A (ko) 2002-01-09
FR2810979A1 (fr) 2002-01-04
ES2227088T3 (es) 2005-04-01
US20040224993A1 (en) 2004-11-11
EP1170288B9 (fr) 2005-01-26
HUP0102723A3 (en) 2002-11-28
DE60104776T2 (de) 2005-09-01
ATE273283T1 (de) 2004-08-15
CA2352405C (fr) 2006-10-03
DK1170288T3 (da) 2004-11-29
TR200402069T4 (tr) 2004-09-21
KR100485018B1 (ko) 2005-04-25
CN1337395A (zh) 2002-02-27
EA005128B1 (ru) 2004-12-30
BR0102607A (pt) 2002-05-28

Similar Documents

Publication Publication Date Title
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PE20020566A1 (es) DERIVADOS DE FENILACETAMIDO-PIRAZOLES COMO INHIBIDORES DE LA cdk/CICLINA QUINASA
AR036659A1 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
DK1263730T3 (da) Aminderivater til behandling af apoptose
AR038044A1 (es) Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR030558A1 (es) COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA,
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR036598A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen potente actividad antagonista de cb1
UY26872A1 (es) Derivados de la 4- fenil piridina
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR043199A1 (es) Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes
AR035417A1 (es) Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
ES2253568T3 (es) Compuestos heterociclicos para el uso en el tratamiento de los trastornos de las vias urinarias.
AR031526A1 (es) Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento.
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
AR041882A1 (es) Compuestos de imidazopiridina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR033942A1 (es) Compuestos de monofluoroalquilo aplicables en la potenciacion de los compuestos intermediarios utilizables en la sintesis de dichos compuestos de monofluoralquilo; composiciones farmaceuticas formuladas con dichos compuestos potenciadores y metodos para la potenciacion de las funciones de dichos rec
ATE479657T1 (de) N-(aryl)-2-arylethensulfonamide und ihre therapeutischen anwendungen

Legal Events

Date Code Title Description
FG Grant, registration